Insights into the epidemiology and management of lupus nephritis from the US rheumatologist's perspective

Kidney International

Volumn 90, Issue 3, 2016, Pages 487-492

  Hoover, Paul J ^a   Costenbader, Karen H ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

epidemiology; glomerulonephritis; lupus

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; HYDROXYCHLOROQUINE; METHYLPREDNISOLONE; MYCOPHENOLATE MOFETIL; RITUXIMAB; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT;

DISEASE ASSOCIATION; DISEASE SEVERITY; END STAGE RENAL DISEASE; HEALTH CARE ACCESS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; LUPUS ERYTHEMATOSUS NEPHRITIS; MASS SCREENING; MEDICAID; MULTICENTER STUDY (TOPIC); OBSERVATIONAL STUDY; POPULATION RESEARCH; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; REMISSION; RISK FACTOR; SHORT SURVEY; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME; TREATMENT RESPONSE; UNITED STATES; ADJUVANT CHEMOTHERAPY; HEALTH CARE DELIVERY; LUPUS NEPHRITIS; MEDICATION COMPLIANCE; ORAL DRUG ADMINISTRATION; RHEUMATOLOGIST; SOCIOECONOMICS;

ADMINISTRATION, ORAL; CHEMOTHERAPY, ADJUVANT; GLUCOCORTICOIDS; HEALTH SERVICES ACCESSIBILITY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; LUPUS NEPHRITIS; MEDICAID; MEDICATION ADHERENCE; PRACTICE GUIDELINES AS TOPIC; PREVALENCE; RHEUMATOLOGISTS; RISK FACTORS; SOCIOECONOMIC FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84994231681     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1016/j.kint.2016.03.042     Document Type: Short Survey

References (47)

1. 1 Ward, M.M., Prevalence of physician-diagnosed systemic lupus erythematosus in the United States: results from the third national health and nutrition examination survey. J Womens Health (Larchmt) 13 (2004), 713–718.
2. 2 Helmick, C.G., Felson, D.T., Lawrence, R.C., et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum 58 (2008), 15–25.
3. 3 Lawrence, R.C., Felson, D.T., Helmick, C.G., et al., National Arthritis Data Workgroup. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum 58 (2008), 26–35.
4. 4 Tektonidou MG, Dasgupta A, Ward MM. Risk of end-stage renal disease in patients with lupus nephritis, 1970 to 2015: a systematic review and Bayesian meta-analysis [e-pub ahead of print]. Arthritis Rheumatol. http://dx.doi.org/10.1002/art.39594. Accessed February 1, 2016.
5. 5 Lim, S.S., Bayakly, A.R., Helmick, C.G., et al. The incidence and prevalence of systemic lupus erythematosus, 2002–2004: the Georgia Lupus Registry. Arthritis Rheumatol 66 (2014), 357–368.
6. 6 Somers, E.C., Marder, W., Cagnoli, P., et al. Population-based incidence and prevalence of systemic lupus erythematosus: the Michigan Lupus Epidemiology and Surveillance program. Arthritis Rheumatol 66 (2014), 369–378.
7. 7 Feldman, C.H., Hiraki, L.T., Liu, J., et al. Epidemiology and sociodemographics of systemic lupus erythematosus and lupus nephritis among US adults with Medicaid coverage, 2000–2004. Arthritis Rheum 65 (2013), 753–763.
8. 8 Hiraki, L.T., Feldman, C.H., Liu, J., et al. Prevalence, incidence, and demographics of systemic lupus erythematosus and lupus nephritis from 2000 to 2004 among children in the US Medicaid beneficiary population. Arthritis Rheum 64 (2012), 2669–2676.
9. 9 Tucker, L.B., Uribe, A.G., Fernandez, M., et al. Adolescent onset of lupus results in more aggressive disease and worse outcomes: results of a nested matched case-control study within LUMINA, a multiethnic US cohort (LUMINA LVII). Lupus 17 (2008), 314–322.
10. 10 Ward, M.M., Access to care and the incidence of endstage renal disease due to systemic lupus erythematosus. J Rheumatol 37 (2010), 1158–1163.
11. 11 FitzGerald, J.D., Battistone, M., Brown, C.R. Jr., et al., for the American College of Rheumatology Committee on Rheumatology Training and Workforce Issues. Regional distribution of adult rheumatologists. Arthritis Rheum 65 (2013), 3017–3025.
12. 12 Oyoo, G.O., Mody, G.M., Report on the Fifth African League Against Rheumatism Congress in Nairobi, Kenya. Clin Rheumatol 26 (2007), 1033–1035.
13. 13 Yazdany, J., Feldman, C.H., Liu, J., et al. Quality of care for incident lupus nephritis among Medicaid beneficiaries in the United States. Arthritis Care Res (Hoboken) 66 (2014), 617–624.
14. 14 Balow, J.E., Clinical presentation and monitoring of lupus nephritis. Lupus 14 (2005), 25–30.
15. 15 Hanly, J.G., O'Keeffe, A.G., Su, L., et al. The frequency and outcome of lupus nephritis: results from an international inception cohort study. Rheumatology (Oxford) 55 (2016), 252–262.
16. 16 Guidelines for referral and management of systemic lupus erythematosus in adults. American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Guidelines. Arthritis Rheum 42 (1999), 1785–1796.
17. 17 Hahn, B.H., McMahon, M.A., Wilkinson, A., et al., American College of Rheumatology. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken) 64 (2012), 797–808.
18. 18 Anders, H.-J., Rovin, B., A pathophysiology-based approach to the diagnosis and treatment of lupus nephritis. Kidney Int 90 (2016), 493–501.
19. 19 Markowitz, G.S., D'Agati, V.D., The ISN/RPS 2003 classification of lupus nephritis: an assessment at 3 years. Kidney Int 71 (2007), 491–495.
20. 20 Hiramatsu, N., Kuroiwa, T., Ikeuchi, H., et al. Revised classification of lupus nephritis is valuable in predicting renal outcome with an indication of the proportion of glomeruli affected by chronic lesions. Rheumatology (Oxford) 47 (2008), 702–707.
21. 21 Hsieh, C., Chang, A., Brandt, D., et al. Predicting outcomes of lupus nephritis with tubulointerstitial inflammation and scarring. Arthritis Care Res (Hoboken) 63 (2011), 865–874.
22. 22 Wilhelmus S, Bajema IM, Bertsias GK, et al. Lupus nephritis management guidelines compared [e-pub ahead of print]. Nephrol Dial Transplant. pii: gfv102. Accessed February 1, 2016.
23. 23 Schoenfeld, S.R., Kasturi, S., Costenbader, K.H., The epidemiology of atherosclerotic cardiovascular disease among patients with SLE: a systematic review. Semin Arthritis Rheum 43 (2013), 77–95.
24. 24 Symmons, D.P., Gabriel, S.E., Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE. Nat Rev Rheumatol 7 (2011), 399–408.
25. 25 Muangchan, C., van Vollenhoven, R.F., Bernatsky, S.R., et al. Treatment algorithms in systemic lupus erythematosus. Arthritis Care Res (Hoboken) 67 (2015), 1237–1245.
26. 26 Clowse, M.E., Behera, M.A., Anders, C.K., et al. Ovarian preservation by GnRH agonists during chemotherapy: a meta-analysis. J Womens Health (Larchmt) 18 (2009), 311–319.
27. 27 Dooley, M.A., Jayne, D., Ginzler, E.M., et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 365 (2011), 1886–1895.
28. 28 Appel, G.B., Contreras, G., Dooley, M.A., et al., for the Aspreva Lupus Management Study Group. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 20 (2009), 1103–1112.
29. 29 ACCESS Trial Group. Treatment of lupus nephritis with abatacept: the Abatacept and Cyclophosphamide Combination Efficacy and Safety Study. Arthritis Rheumatol 66 (2014), 3096–3104.
30. 30 Rovin, B.H., Furie, R., Latinis, K., et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 64 (2012), 1215–1226.
31. 31 Grootscholten, C., Berden, J.H., Discontinuation of immunosuppression in proliferative lupus nephritis: is it possible?. Nephrol Dial Transplant 21 (2006), 1465–1469.
32. 32 Costenbader, K.H., Desai, A., Alarcon, G.S., et al. Trends in the incidence, demographics, and outcomes of end-stage renal disease due to lupus nephritis in the US from 1995 to 2006. Arthritis Rheum 63 (2011), 1681–1688.
33. 33 Korbet, S.M., Lewis, E.J., Schwartz, M.M., et al., for the Lupus Nephritis Collaborative Study Group. Factors predictive of outcome in severe lupus nephritis. Am J Kidney Dis 35 (2000), 904–914.
34. 34 Chen, Y.E., Korbet, S.M., Katz, R.S., et al., for the Collaborative Study Group. Value of a complete or partial remission in severe lupus nephritis. Clin J Am Soc Nephrol 3 (2008), 46–53.
35. 35 Marengo, M.F., Waimann, C.A., de Achaval, S., et al. Measuring therapeutic adherence in systemic lupus erythematosus with electronic monitoring. Lupus 21 (2012), 1158–1165.
36. 36 Feldman, C.H., Yazdany, J., Guan, H., et al. Medication nonadherence is associated with increased subsequent acute care utilization among Medicaid beneficiaries with systemic lupus erythematosus. Arthritis Care Res (Hoboken) 67 (2015), 1712–1721.
37. 37 Durcan, L., Clarke, W.A., Magder, L.S., Petri, M., Hydroxychloroquine blood levels in systemic lupus erythematosus: clarifying dosing controversies and improving adherence. J Rheumatol 42 (2015), 2092–2097.
38. 38 Mohan, C., Putterman, C., Genetics and pathogenesis of systemic lupus erythematosus and lupus nephritis. Nat Rev Nephrol 11 (2015), 329–341.
39. 39 Freedman, B.I., Langefeld, C.D., Andringa, K.K., et al., for the Lupus Nephritis—End-Stage Renal Disease Consortium. End-stage renal disease in African Americans with lupus nephritis is associated with APOL1. Arthritis Rheumatol 66 (2014), 390–396.
40. 40 Houssiau, F.A., D'Cruz, D., Sangle, S., et al., for the MAINTAIN Nephritis Trial Group. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Ann Rheum Dis 69 (2010), 2083–2089.
41. 41 Schwartz, N., Goilav, B., Putterman, C., The pathogenesis, diagnosis and treatment of lupus nephritis. Curr Opin Rheumatol 26 (2014), 502–509.
42. 42 Feldman, C.H., Hiraki, L.T., Winkelmayer, W.C., et al. Serious infections among adult Medicaid beneficiaries with systemic lupus erythematosus and lupus nephritis. Arthritis Rheumatol 67 (2015), 1577–1585.
43. 43 van Assen, S., Agmon-Levin, N., Elkayam, O., et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 70 (2011), 414–422.
44. 44 Ruiz-Irastorza, G., Danza, A., Khamashta, M., Glucocorticoid use and abuse in SLE. Rheumatology (Oxford) 51 (2012), 1145–1153.
45. 45 Grossman, J.M., Gordon, R., Ranganath, V.K., et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken) 62 (2010), 1515–1526.
46. 46 Lightstone, L., Minimising steroids in lupus nephritis—will B cell depletion pave the way?. Lupus 22 (2013), 390–399.
47. 47 Condon, M.B., Ashby, D., Pepper, R.J., et al. Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis 72 (2013), 1280–1286.